Hyperactivity of the JAK/STAT pathway has been demonstrated in patients with MS, and indeed its inhibition might halt MS progression (Benveniste et al. 2014; Liu et al. 2014; Dang et al. 2021). Here, SOAT1 is linked to myeloid sarcoma.